Radioligand therapies (RLT) addressing the prostate-specific membrane antigen (PSMA), have shown most promising results regarding clinical safety and efficacy in patients with progressive metastasized castration-resistance prostate cancer (mCRPC) that are no longer responsive to treatments based on current guidelines [1,2,3,4,5]. Here, FOLH1 is linked to prostate carcinoma.